Skip to main content
SpringerLink
Log in

Interventional Trials to Prevent Diabetes: Diabetes Prevention Program

  • Chapter
  • First Online:
Prevention of Type 2 Diabetes

Abstract

The largest randomized controlled clinical trial in diabetes prevention is the Diabetes Prevention Program (DPP), funded by the US National Institutes of Health. By design, the DPP is the most diverse prospective study to date in diabetes prevention.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Edelstein SL, Knowler WC, Bain RP, Andres R, Barrett-Connor EL, Dowse GK, et al. Predictors of progression from impaired glucose tolerance to NIDDM: an analysis of six prospective studies. Diabetes. 1997;46:701–10.

    Article  PubMed  CAS  Google Scholar 

  2. Group The Diabetes Prevention Program Research. The Diabetes Prevention Program: design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care. 1999;22:623–34.

    Article  Google Scholar 

  3. Eriksson KF, Lindgarde F. Prevention of type II (non-insulin-dependent) diabetes mellitus by diet and physical exercise: the 6-year Malmo Feasibility Study. Diabetologia. 1991;34:891–8.

    Article  PubMed  CAS  Google Scholar 

  4. Pan XR, Li GW, Hu YH, Wang JX, Yang WY, An ZX, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care. 1997;20:537–44.

    Article  PubMed  CAS  Google Scholar 

  5. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al.; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle or metformin. N Engl J Med. 2002;346:393–403.

    Article  Google Scholar 

  6. Rubin RR, Fujimoto WY, Marrero DG, Brenneman T, Charleston JB, Edelstein SL, et al.; DPP Research Group. The Diabetes Prevention Program: recruitment methods and results. Control Clin Trials. 2002;23:157–71.

    Article  Google Scholar 

  7. Fujimoto WY. Background and recruitment data for the U.S. Diabetes Prevention Program. Diabetes Care. 2000;23 Suppl 2:B11–3.

    PubMed  Google Scholar 

  8. Diabetes Prevention Program Research Group. Strategies to identify adults at high risk for type 2 diabetes: the Diabetes Prevention Program. Diabetes Care. 2005;28:138–44.

    Article  Google Scholar 

  9. Wylie-Rosett J, Delahanty L. An integral role of the dietitian: implications of the Diabetes Prevention Program. J Am Diet Assoc. 2002;102:1065–8.

    PubMed  Google Scholar 

  10. Hoskin M, Begay SH, Bolin P, Hermes J, Ingraham LE, Killean T, et al. Providing lifestyle interventions in Native American communities. Obesity Management. 2005;1:251–5.

    Article  Google Scholar 

  11. Knowler WC, Hamman RF, Edelstein SL, Barrett-Connor E, Ehrmann DA, Walker EA, et al.; Diabetes Prevention Program Research Group. Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program. Diabetes. 2005;54:1150–6.

    Article  Google Scholar 

  12. Group The Diabetes Prevention Program Research. The Diabetes Prevention Program: baseline characteristics of the randomized cohort. Diabetes Care. 2000;23:1619–29.

    Article  Google Scholar 

  13. Diabetes Prevention Program Research Group, Crandall J, Schade D, Ma Y, Fujimoto WY, Barrett-Connor E, et al. The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes. J Gerontol A Biol Sci Med Sci. 2006;61:1075–81.

    Article  PubMed  Google Scholar 

  14. Ratner RE, Christophi CA, Metzger BE, Dabelea D, Bennett PH, Pi-Sunyer X, et al.; Diabetes Prevention Program Research Group. Prevention of diabetes in women with a history of gestational diabetes: effects of metformin and lifestyle interventions. J Clin Endocrinol Metab. 2008;93:4774–9.

    Article  Google Scholar 

  15. Walker EA, Molitch M, Kramer MK, Kahn S, Ma Y, Edelstein S, et al. Adherence to preventive medications: predictors and outcomes in the Diabetes Prevention Program. Diabetes Care. 2006;29:1997–2002.

    Article  PubMed  Google Scholar 

  16. Wing RR, Hamman RF, Bray GA, Delahanty L, Edelstein SL, Hill JO, et al.; Diabetes Prevention Program Research Group. Achieving weight and activity goals among diabetes prevention program lifestyle participants. Obes Res. 2004;12:1426–34.

    Article  Google Scholar 

  17. Delahanty LM, Conroy MB, Nathan DM; Diabetes Prevention Program Research Group. Psychological predictors of physical activity in the diabetes prevention program. J Am Diet Assoc. 2006;106:698–705.

    Article  Google Scholar 

  18. Rubin RR, Ma Y, Marrero DG, Peyrot M, Barrett-Connor EL, Kahn SE, et al.; Diabetes Prevention Program Research Group. Elevated depression symptoms, antidepressant medicine use, and risk of developing diabetes during the diabetes prevention program. Diabetes Care. 2008;31:420–6.

    Google Scholar 

  19. Crandall JP, Polsky S, Howard AA, Perreault L, Bray GA, Barrett-Connor E, et al.; Diabetes Prevention Program Research Group. Alcohol consumption and diabetes risk in the Diabetes Prevention Program. Am J Clin Nutr. 2009;90:595–601.

    Article  Google Scholar 

  20. Hamman RF, Wing RR, Edelstein SL, Lachin JM, Bray GA, Delahanty L, et al. Effect of weight loss with lifestyle intervention on risk of diabetes. Diabetes Care. 2006;29:2102–7.

    Article  PubMed  Google Scholar 

  21. Fujimoto WY, Jablonski KA, Bray GA, Kriska A, Barrett-Connor E, Haffner S, et al.; Diabetes Prevention Program Research Group. Body size and shape changes and the risk of diabetes in the diabetes prevention program. Diabetes. 2007;56:1680–5.

    Article  Google Scholar 

  22. Group The Diabetes Prevention Program Research. Relationship of body size and shape to the development of diabetes in the diabetes prevention program. Obesity. 2006;14:2107–17.

    Article  Google Scholar 

  23. Lachin JM, Christophi CA, Edelstein SL, Ehrmann DA, Hamman RF, Kahn SE, et al.; DDK Research Group. Factors associated with diabetes onset during metformin versus placebo therapy in the diabetes prevention program. Diabetes. 2007;56:1153–9.

    Article  Google Scholar 

  24. Mather KJ, Funahashi T, Matsuzawa Y, Edelstein S, Bray GA, Kahn SE, et al.; Diabetes Prevention Program. Adiponectin, change in adiponectin, and progression to diabetes in the Diabetes Prevention Program. Diabetes. 2008;57:980–6.

    Article  Google Scholar 

  25. Friedman AN, Marrero D, Ma Y, Ackermann R, Narayan KM, Barrett-Connor E, et al.; Diabetes Prevention Program Research Group. Value of urinary albumin-to-creatinine ratio as a predictor of type 2 diabetes in pre-diabetic individuals. Diabetes Care. 2008;31:2344–8.

    Article  Google Scholar 

  26. Mayer-Davis EJ, Sparks KC, Hirst K, Costacou T, Lovejoy JC, Regensteiner JG, et al.; Diabetes Prevention Program Research Group. Dietary intake in the diabetes prevention program cohort: baseline and 1-year post randomization. Ann Epidemiol. 2004;14:763–72.

    Article  Google Scholar 

  27. Kitabchi AE, Temprosa M, Knowler WC, Kahn SE, Fowler SE, Haffner SM, et al.; Diabetes Prevention Program Research Group. Role of insulin secretion and sensitivity in the evolution of type 2 diabetes in the diabetes prevention program: effects of lifestyle intervention and metformin. Diabetes. 2005;54:2404–14.

    Article  Google Scholar 

  28. Diabetes Prevention Program Research Group. Hypertension, insulin, and proinsulin in participants with impaired glucose tolerance. Hypertension. 2002;40:679–86.

    Article  Google Scholar 

  29. Ratner R, Goldberg R, Haffner S, Marcovina S, Orchard T, Fowler S, et al.; Diabetes Prevention Program Research Group. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the diabetes prevention program. Diabetes Care. 2005;28:888–94.

    Article  Google Scholar 

  30. Diabetes Prevention Program Research Group. Lipid, lipoproteins, C-reactive protein, and hemostatic factors at baseline in the diabetes prevention program. Diabetes Care. 2005;28:2472–9.

    Article  Google Scholar 

  31. Haffner S, Temprosa M, Crandall J, Fowler S, Goldberg R, Horton E, et al.; Diabetes Prevention Program Research Group. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes. 2005;54:1566–72.

    Article  Google Scholar 

  32. Orchard TJ, Temprosa M, Goldberg R, Haffner S, Ratner R, Marcovina S, et al.; Diabetes Prevention Program Research Group. The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial. Ann Intern Med. 2005;142:611–9.

    Google Scholar 

  33. Diabetes Prevention Program Research Group. Changes in albumin excretion in the diabetes prevention program. Diabetes Care. 2009;32:720–5.

    Article  Google Scholar 

  34. Diabetes Prevention Program Research Group. The prevalence of retinopathy in impaired glucose tolerance and recent-onset diabetes in the Diabetes Prevention Program. Diabet Med. 2007;24:137–44.

    Article  Google Scholar 

  35. Carnethon MR, Prineas RJ, Temprosa M, Zhang ZM, Uwaifo G, Molitch ME; Diabetes Prevention Program Research Group. The association among autonomic nervous system function, incident diabetes, and intervention arm in the Diabetes Prevention Program. Diabetes Care. 2006;29:914–9.

    Article  Google Scholar 

  36. Brown JS, Wing R, Barrett-Connor E, Nyberg LM, Kusek JW, Orchard TJ, et al.; Diabetes Prevention Program Research Group. Lifestyle intervention is associated with lower prevalence of urinary incontinence: the Diabetes Prevention Program. Diabetes Care. 2006;29:385–90.

    Article  Google Scholar 

  37. Florez JC, Jablonski KA, Bayley N, Pollin TI, de Bakker PI, Shuldiner AR, et al.; Diabetes Prevention Program Research Group. TCF7L2 polymorphisms and progression to diabetes in the Diabetes Prevention Program. N Engl J Med. 2006;355:241–50.

    Article  Google Scholar 

  38. Grant SF, Thorleifsson G, Reynisdottir I, Benediktsson R, Manolescu A, Sainz J, et al. Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nat Genet. 2006;38:320–3.

    Article  PubMed  CAS  Google Scholar 

  39. Florez JC, Jablonski KA, Sun MW, Bayley N, Kahn SE, Shamoon H, et al.; Diabetes Prevention Program Research Group. Effects of the type 2 diabetes-associated PPARG P12A polymorphism on progression to diabetes and response to troglitazone. J Clin Endocrinol Metab. 2007;92:1502–9.

    Article  Google Scholar 

  40. Florez JC, Jablonski KA, Kahn SE, Franks PW, Dabelea D, Hamman RF, et al. Type 2 diabetes-associated missense polymorphisms KCNJ11 E23K and ABCC8 A1369S influence progression to diabetes and response to interventions in the Diabetes Prevention Program. Diabetes. 2007;56:531–6.

    Article  PubMed  CAS  Google Scholar 

  41. Moore AF, Jablonski KA, McAteer JB, Saxena R, Pollin TI, Franks PW, et al.; Diabetes Prevention Program Research Group. Extension of type 2 diabetes genome-wide association scan results in the diabetes prevention program. Diabetes. 2008;5:2503–10.

    Google Scholar 

  42. Moore AF, Jablonski KA, Mason CC, McAteer JB, Arakaki RF, Goldstein BJ, et al.; Diabetes Prevention Program Research Group. The association of ENPP1 K121Q with diabetes incidence is abolished by lifestyle modification in the diabetes prevention program. J Clin Endocrinol Metab. 2009;94:449–55.

    Article  Google Scholar 

  43. Jablonski KA, McAteer JB, de Bakker PI, Franks PW, Pollin TI, Hanson RL, et al.; Diabetes Prevention Program Research Group. Common variants in 40 genes assessed for diabetes incidence and response to metformin and lifestyle intervention in the diabetes prevention program. Diabetes. 2010;59:2672–81.

    Article  Google Scholar 

  44. Diabetes Prevention Program Research Group. Effects of withdrawal from metformin on the development of diabetes in the diabetes prevention program. Diabetes Care. 2003;26:977–80.

    Article  Google Scholar 

  45. Li G, Zhang P, Wang J, Gregg EW, Yang W, Gong Q, et al. The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20-year follow-up study. Lancet. 2008;371:1783–9.

    Article  PubMed  Google Scholar 

  46. Lindström J, Ilanne-Parikka P, Peltonen M, Aunola S, Eriksson JG, Hemiö K, et al.; Finnish Diabetes Prevention Study Group. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet. 2006;368:1673–9.

    Article  Google Scholar 

  47. Diabetes Prevention Program Research Group. 10-Year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet. 2009;374:1677–86.

    Article  Google Scholar 

  48. Benjamin SM, Valdez R, Vinicor F. Diabetes prevention. Author reply. N Engl J Med. 2002;346:1829–30.

    Article  PubMed  Google Scholar 

  49. Herman WH, Hoerger TJ, Brandle M, Hicks K, Sorensen S, Zhang P, et al.; Diabetes Prevention Program Research Group. The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Ann Intern Med. 2005;142:323–32.

    Google Scholar 

  50. Ratner RE; Diabetes Prevention Program Research Group. An update on the Diabetes Prevention Prgoram. Endocr Pract. 2006;12 Suppl 1:20–4.

    Google Scholar 

  51. Diabetes Prevention Program Research Group. Within-trial cost-effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care. 2003;26:2518–23.

    Article  Google Scholar 

  52. Herman WH, Edelstein SL, Ratner RE, Montez MG, Ackermann RT, Orchard TJ, et al.; The Diabetes Prevention Program Research Group. The 10-year cost-effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes mellitus: an intent-to-treat analysis of diabetes prevention. American Diabetes Association 71st Scientific Sessions; 2011.

    Google Scholar 

  53. American Diabetes Association. Standards of medical care in diabetes—2011. Diabetes Care. 2011;4:S11–61.

    Article  Google Scholar 

  54. Nathan DM, Davidson MB, DeFronzo RA, Heine RJ, Henry RR, Pratley R, et al.; American Diabetes Association. Impaired fasting glucose and impaired glucose tolerance: implications for care. Diabetes Care. 2007;30:753–9.

    Article  Google Scholar 

  55. Garber AJ, Handelsman Y, Einhorn D, Bergman DA, Bloomgarden ZT, Fonseca V, et al. Diagnosis and management of prediabetes in the continuum of hyperglycemia: when do the risks of diabetes begin? A consensus statement from the American College of Endocrinology and the American Association of Clinical Endocrinologists. Endocr Pract. 2008;14:933–46.

    PubMed  Google Scholar 

  56. Rosenzweig JL, Ferrannini E, Grundy SM, Haffner SM, Heine RJ, Horton ES, et al. Primary prevention of cardiovascular disease and type 2 diabetes in patients at metabolic risk: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2008;93:3671–89.

    Article  PubMed  CAS  Google Scholar 

  57. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association for the prevention and management of diabetes in Canada. Can J Diabetes. 2008;32 Suppl 1:S17–9.

    Google Scholar 

  58. Indian Health Service. Guidelines for care of adults with pre-diabetes and/or the metabolic syndrome in clinical settings. 2008. http://www.ihs.gov/MedicalPrograms/Diabetes/HomeDocs/Tools/ClinicalGuidelines/PreDiabetes_Guidelines_0209.pdf. Accessed 19 April 2011.

  59. U.S. Preventive Services Task Force. Screening for type 2 diabetes mellitus in adults: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2008;148:846–54.

    Google Scholar 

  60. Twigg SM, Kamp MC, Davis TM, Neylon EK, Flack JR; Australian Diabetes Society; Australian Diabetes Educators Association. Prediabetes: a position statement from the Australian Diabetes Society and Australian Diabetes Educators Association. Med J Aust. 2007;186:461–5.

    Google Scholar 

  61. Alberti KG, Zimmet P, Shaw J. International diabetes federation: a consensus on Type 2 diabetes prevention. Diabet Med. 2007;24:451–63.

    Article  PubMed  CAS  Google Scholar 

  62. Patient Protection and Affordable Care Act, Pub. L. No. 111-148, §10409, 124 Stat. 119, 978; 2010.

    Google Scholar 

  63. Centers for Disease Control and Prevention. National Diabetes Prevention Program. 2011. http://www.cdc.gov/diabetes/projects/prevention_program.htm. Accessed 16 Feb 2011.

  64. Ackermann RT, Finch EA, Brizendine E, Zhou H, Marrero DG. Translating the Diabetes Prevention Program into the community. The DEPLOY Pilot Study. Am J Prev Med. 2008;35:357–63.

    Article  PubMed  Google Scholar 

  65. National Institutes of Health/National Institute of Diabetes and Digestive and Kidney Diseases. Advances and emerging opportunities in diabetes research: a strategic planning report of the DMICC, Final Plan. 2011. http://conferences.thehillgroup.com/DRSP/PDF_508/DRAFT_DSP_Full02.22.10.pdf. Accessed 16 Feb 2011.

Download references

Author information

Authors and Affiliations

  1. MedStar Health Research Institute, 6525 Belcrest Road, Suite #700, Hyattsville, MD, 20782, USA

    Vanita R. Aroda MD

  2. Georgetown University School of Medicine, Washington, DC, USA

    Vanita R. Aroda MD

  3. MedStar Health Research Institute, Georgetown University School of Medicine, Washington, DC, USA

    Robert E. Ratner MD

Authors
  1. Vanita R. Aroda MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Robert E. Ratner MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Vanita R. Aroda MD .

Editor information

Editors and Affiliations

  1. , Department of Medicine, Mount Sinai School of Medicine, 1 Gustave L. Levy Place, New York, 10029, USA

    Derek LeRoith

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer Science+Business Media New York

About this chapter

Cite this chapter

Aroda, V.R., Ratner, R.E. (2012). Interventional Trials to Prevent Diabetes: Diabetes Prevention Program. In: LeRoith, D. (eds) Prevention of Type 2 Diabetes. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-3314-9_9

Download citation

  • DOI: https://doi.org/10.1007/978-1-4614-3314-9_9

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4614-3313-2

  • Online ISBN: 978-1-4614-3314-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation